<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-29T16:29:18.7466+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:omga="http://omegatherapeutics.com/20240528" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_fd6944ff-1d30-42d0-b35b-f62946dd1f97" name="dei:EntityCentralIndexKey" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce">0001850838</ix:nonNumeric><ix:nonNumeric id="F_7a44adb3-0759-413d-af01-4697043c12d7" name="dei:AmendmentFlag" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="omga-20240528.xsd"/></ix:references><ix:resources><xbrli:context id="C_1d36ca84-b244-4faa-9e52-229482411dce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001850838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-28</xbrli:startDate><xbrli:endDate>2024-05-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="new_section"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">___________________________________</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6779c8de-16b6-40dc-af82-e4168a1af550" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ___________________________________</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Securities Exchange Act of 1934</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa74eaee-d0d1-4db8-9062-95781798bf14" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">May 28, 2024</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> __________________________________</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5983bea0-4008-4b86-8469-73bb31537d47" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Omega Therapeutics, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as specified in its charter)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">__________________________________</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:0.556%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:30.854%;"/>
    <td style="width:3.519%;"/>
    <td style="width:31.054%;"/>
    <td style="width:3.519%;"/>
    <td style="width:31.054%;"/>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_0a12e8c4-d892-4558-b2a4-f9a3be2893e7" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_c74f4e72-11c8-4c12-b213-4c06a7f27e0e" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-40657</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b7b4c6e4-9e05-4cb0-afeb-b8eac1709e3f" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">81-3247585</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(Commission</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">File Number)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(I.R.S. Employer</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05bbee35-2d12-4194-ac4b-362f82612f21" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">140 First Street</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68b11c65-8117-4515-9f4d-4429eb8a1d54" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 501</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9b55c1e4-6bed-4a07-a111-f371f12fcc14" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cambridge</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b999c90e-c492-48e6-8d80-d1d8d3596ef1" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42074b45-ff68-4b00-93c5-d9db3ea191aa" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">02141</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices) (Zip Code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: (</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1d0f0b7-7295-43de-8e30-6d8cb62bd087" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7d442b7-8271-467e-a336-b14a5856db15" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">949-4360</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">N/A</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ____________________________________</span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_756ad727-517c-469d-abb4-e3917118b33f" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:WrittenCommunications" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61551;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_072555d5-c60b-4340-adab-cd8991ff4c3c" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:SolicitingMaterial" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61551;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_1b819cf4-d9fc-44fc-88d7-e67efb54a04a" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61551;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:'Wingdings',serif;"><ix:nonNumeric id="F_a3465d3f-2e84-416c-bd2c-c277d9b1fc78" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Wingdings',serif;min-width:fit-content;">&#61551;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.76%;"/>
    <td style="width:1%;"/>
    <td style="width:29.62%;"/>
    <td style="width:1%;"/>
    <td style="width:32.62%;"/>
   </tr>
   <tr style="height:18pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.007in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-left:0.007in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.007in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:20.9pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_1d31e7ae-b3a3-4e27-9824-3152aa4077b8" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_4d30c900-0ce4-4a26-9a2a-b976ed3ca97f" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">OMGA</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.007in;vertical-align:top;padding-right:0.007in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_eae946a0-da2e-4e4d-9065-b8330467e40a" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_b4c9525f-6a3e-4008-882a-df3f3d1b3f90" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e7d8eda5-4475-4fa0-9105-3b2dcde54d2f" contextRef="C_1d36ca84-b244-4faa-9e52-229482411dce" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2024, Omega Therapeutics, Inc. (the &#8220;Company&#8221;) and Yan Moore, M.D., the Company&#8217;s Chief Medical Officer, agreed to terminate his employment effective as of May 31, 2024. In connection with the termination, Dr. Moore entered into a separation agreement with the Company containing a release of claims that provides for the severance payments and benefits set forth in his employment agreement with the Company. The Company expects seamless continuation of its Phase 1/2 clinical trial for OTX-2002 for the treatment of hepatocellular carcinoma, and has initiated a search for his successor.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01. Regulation FD Disclosure.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 28, 2024, the Company appointed Kaan Certel, Ph.D. as its Chief Business Officer, effective May 28, 2024. Dr. Certel has more than 20 years of biopharmaceutical industry and academic experience and will be responsible for global business development activities including strategic partnerships.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Forward-Looking Statements Disclaimer</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the seamless continuation of the Company&#8217;s Phase 1/2 clinical trial for OTX-2002 and Dr. Certel&#8217;s anticipated role at the Company. These forward-looking statements are based on the Company&#8217;s management&#8217;s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the important factors discussed under the caption &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and the Company&#8217;s other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Any such forward-looking statements represent management&#8217;s estimates as of the date of this Form 8-K. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause the Company&#8217;s views to change. These forward-looking statements should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date of this Form 8-K.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.253%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:7pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.82%;"/>
    <td style="width:4.22%;"/>
    <td style="width:6.82%;"/>
    <td style="width:33.14%;"/>
   </tr>
   <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:12.95pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:23.05pt;padding-left:0.042in;vertical-align:bottom;"><p style="margin-left:23.05pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 30, 2024</span></p></td>
    <td colspan="3" style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Omega Therapeutics, Inc.</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td colspan="2" style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mahesh Karande</span></p></td>
   </tr>
   <tr style="height:17.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:1pt solid;padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mahesh Karande</span></p></td>
   </tr>
   <tr style="height:15.1pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.267%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "omga-20240528.htm", "description": "8-K", "secsgml_size_bytes": 47966}]
{"company-data": {"conformed-name": "Omega Therapeutics, Inc.", "cik": "0001850838", "assigned-sic": "2836", "organization-name": "03 Life Sciences", "irs-number": "000000000", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-40657", "film-number": "241006382"}, "business-address": {"street1": "140 FIRST STREET, SUITE 501", "city": "CAMBRIDGE", "state": "MA", "zip": "02141", "phone": "(617) 949-4360"}, "mail-address": {"street1": "140 FIRST STREET, SUITE 501", "city": "CAMBRIDGE", "state": "MA", "zip": "02141"}}
8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM
8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
May 28, 2024
__________________________________
Omega Therapeutics, Inc.
(Exact Name of Registrant as specified in its charter)
__________________________________
Delaware
001-40657
81-3247585
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
140 First Street
,
Suite 501
Cambridge
,
Massachusetts
02141
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (
617
)
949-4360
N/A
(Former Name or Former Address, if Changed Since Last Report)
____________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
OMGA
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On May 28, 2024, Omega Therapeutics, Inc. (the "Company") and Yan Moore, M.D., the Company's Chief Medical Officer, agreed to terminate his employment effective as of May 31, 2024. In connection with the termination, Dr. Moore entered into a separation agreement with the Company containing a release of claims that provides for the severance payments and benefits set forth in his employment agreement with the Company. The Company expects seamless continuation of its Phase 1/2 clinical trial for OTX-2002 for the treatment of hepatocellular carcinoma, and has initiated a search for his successor.
Item 7.01. Regulation FD Disclosure.
On May 28, 2024, the Company appointed Kaan Certel, Ph.D. as its Chief Business Officer, effective May 28, 2024. Dr. Certel has more than 20 years of biopharmaceutical industry and academic experience and will be responsible for global business development activities including strategic partnerships.
Forward-Looking Statements Disclaimer
This Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the seamless continuation of the Company's Phase 1/2 clinical trial for OTX-2002 and Dr. Certel's anticipated role at the Company. These forward-looking statements are based on the Company's management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the important factors discussed under the caption "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, and the Company's other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Any such forward-looking statements represent management's estimates as of the date of this Form 8-K. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause the Company's views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 30, 2024
Omega Therapeutics, Inc.
By:
/s/ Mahesh Karande
Mahesh Karande
President and Chief Executive Officer